Skip to content

MJ Pharmaceuticals Inc.: 10-Q filed 2015-10-16

What MJ Pharmaceuticals Inc. reported in its quarterly report filed 2015-10-16 (fiscal Q3 2015): 20 published measures, 66 facts as tagged in accession 0001502629-15-000019.

This filing

Form
10-Q (quarterly report)
Filed
2015-10-16
Fiscal period
fiscal Q3 2015
Accession
0001502629-15-000019 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MJ Pharmaceuticals Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-09-304,901USD
At 2014-12-317,358USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-09-304,402USD
At 2014-12-316,909USD
At 2013-12-310USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-09-304,901USD
At 2015-01-017,358USD
At 2014-12-317,358USD
At 2014-01-010USD
At 2012-02-200USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-07-01 to 2015-09-30-930USD92
2015-01-01 to 2015-09-30-2,507USD273
2012-02-21 to 2015-09-30-14,172USD1318
2014-01-01 to 2014-12-31-7,676USD365
2014-07-01 to 2014-09-30765USD92
2014-01-01 to 2014-09-30-7,758USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2015-01-01 to 2015-09-30-2,507USD273
2012-02-21 to 2015-09-30-14,172USD1318
2014-01-01 to 2014-09-30-7,198USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2015-01-01 to 2015-09-3050USD273
2012-02-21 to 2015-09-3019,073USD1318
2014-01-01 to 2014-09-3014,585USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-09-30-14,172USD
At 2014-12-31-11,665USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2015-07-01 to 2015-09-30185,740,000shares92
2015-01-01 to 2015-09-30185,740,000shares273
2014-07-01 to 2014-09-30111,338,986shares92
2014-01-01 to 2014-09-30111,338,986shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2015-07-01 to 2015-09-300USD/shares92
2015-01-01 to 2015-09-300USD/shares273
2014-07-01 to 2014-09-300USD/shares92
2014-01-01 to 2014-09-300USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2015-01-01 to 2015-09-300USD273
2012-02-21 to 2015-09-300USD1318

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-09-304,901USD
At 2014-12-317,358USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-09-30499USD
At 2014-12-31449USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-07-01 to 2015-09-30930USD92
2015-01-01 to 2015-09-302,507USD273
2012-02-21 to 2015-09-3017,893USD1318
2014-07-01 to 2014-09-30600USD92
2014-01-01 to 2014-09-309,123USD273

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2015-07-01 to 2015-09-300USD92
2015-01-01 to 2015-09-300USD273
2012-02-21 to 2015-09-303,721USD1318
2014-07-01 to 2014-09-301,365USD92
2014-01-01 to 2014-09-301,365USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-09-30185,740,000shares
At 2014-12-31185,740,000shares
At 2013-12-3139,890,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-09-300USD
At 2014-12-310USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-07-01 to 2015-09-300USD92
2015-01-01 to 2015-09-3011USD273
2012-02-21 to 2015-09-304,408USD1318
2014-07-01 to 2014-09-30100USD92
2014-01-01 to 2014-09-303,990USD273

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2015-01-01 to 2015-09-30852USD273
2012-02-21 to 2015-09-304,818USD1318

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2015-01-01 to 2015-09-300USD273
2012-02-21 to 2015-09-3018,574USD1318
2014-01-01 to 2014-09-3014,585USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-09-300USD273
2012-02-21 to 2015-09-300USD1318
2014-01-01 to 2014-09-3044,512USD273

Inspect the source

Entity
MJ Pharmaceuticals Inc. / CIK 0001502629
Captured
SEC response SHA-256
5ce093c694d9161527737dccb4620c6073fa9931928a8199fe9c927e02b1482e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001502629.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))